Recent Company News

• 10:58 AM ET Aug 27, 2026
  

  StreetAccount Summary - European unusual volume traders

• 04:16 PM ET Oct 01, 2026
  

  Nanobiotix appoints Arnd Christ as CFO (€25.40, 0.00)

• 04:17 PM ET Sep 24, 2026
  

  Nanobiotix reports H1 net income (€34.3M) vs FactSet (€20.6M) [1 est] (€27.94, 0.00)

• 12:46 AM ET Sep 19, 2026
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 08:14 AM ET Sep 15, 2026
  

  Nanobiotix assumed buy at Guggenheim Securities; previous rating was buy ($35.73, 0.00)

• 04:53 PM ET Aug 17, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 04:57 AM ET Sep 14, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:01 AM ET Sep 14, 2026
  

  NANOBIOTIX announces complete full cohort Phase 1 results for JNJ-1900 (NBTXR3) in inoperable, recurrent Non-Small Cell Lung Cancer (€31.30, 0.00)